DMU-212 against EGFR-mutant non-small cell lung cancer via AMPK/PI3K/Erk signaling pathway

類似資料

• In Vivo Metabolite Profiling of DMU-212 in Apc^Min/+ Mice Using UHPLC-Q/Orbitrap/LTQ MS
  著者:: Jing Li, 等
  出版事項: (2023-04-01)
• Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study
  著者:: Meng-Xia Li, 等
  出版事項: (2017-04-01)
• AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer
  著者:: Hua Ye, 等
  出版事項: (2020-07-01)
• A Large Real-World Study on the Effectiveness of the Combined Inhibition of EGFR and MET in EGFR-Mutant Non-Small-Cell Lung Cancer After Development of EGFR-TKI Resistance
  著者:: Li Liu, 等
  出版事項: (2021-10-01)
• Overcoming T790M mutant small cell lung cancer with the third‐generation EGFR‐TKI osimertinib
  著者:: Kejing Tang, 等
  出版事項: (2019-02-01)